Cyclic Peptide [R4W4] in Improving the Ability of First-Line Antibiotics to Inhibit \u3cem\u3eMycobacterium tuberculosis\u3c/em\u3e Inside \u3cem\u3ein vitro\u3c/em\u3e Human Granulomas by Hernandez, Joshua et al.
Chapman University 
Chapman University Digital Commons 
Pharmacy Faculty Articles and Research School of Pharmacy 
8-13-2020 
Cyclic Peptide [R4W4] in Improving the Ability of First-Line 
Antibiotics to Inhibit Mycobacterium tuberculosis Inside in vitro 
Human Granulomas 
Joshua Hernandez 
David Ashley 
Ruoqiong Cao 
Rachel Abrahem 
Timothy Nguyen 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.chapman.edu/pharmacy_articles 
 Part of the Amino Acids, Peptides, and Proteins Commons, Bacterial Infections and Mycoses 
Commons, Other Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons, Other 
Pharmacy and Pharmaceutical Sciences Commons, and the Therapeutics Commons 
Cyclic Peptide [R4W4] in Improving the Ability of First-Line Antibiotics to Inhibit 
Mycobacterium tuberculosis Inside in vitro Human Granulomas 
Comments 
This article was originally published in Frontiers in Immunology, volume 11, in 2020. https://doi.org/
10.3389/fimmu.2020.01677 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
Copyright 
The authors 
Authors 
Joshua Hernandez, David Ashley, Ruoqiong Cao, Rachel Abrahem, Timothy Nguyen, Kimberly To, Aram 
Yegiazaryan, Ajayi Akinwale David, Rakesh Kumar Tiwari, and Vishwanath Venketaraman 
ORIGINAL RESEARCH
published: 13 August 2020
doi: 10.3389/fimmu.2020.01677
Frontiers in Immunology | www.frontiersin.org 1 August 2020 | Volume 11 | Article 1677
Edited by:
Thanh Kha Phan,
La Trobe University, Australia
Reviewed by:
Alyce Mayfosh,
La Trobe University, Australia
Alexandro Rodriguez-Rojas,
Freie Universität Berlin, Germany
*Correspondence:
Rakesh Kumar Tiwari
tiwari@chapman.edu
Vishwanath Venketaraman
vvenketaraman@westernu.edu
Specialty section:
This article was submitted to
Microbial Immunology,
a section of the journal
Frontiers in Immunology
Received: 16 February 2020
Accepted: 23 June 2020
Published: 13 August 2020
Citation:
Hernandez J, Ashley D, Cao R,
Abrahem R, Nguyen T, To K,
Yegiazaryan A, Akinwale David A,
Kumar Tiwari R and Venketaraman V
(2020) Cyclic Peptide [R4W4] in
Improving the Ability of First-Line
Antibiotics to Inhibit Mycobacterium
tuberculosis Inside in vitro Human
Granulomas.
Front. Immunol. 11:1677.
doi: 10.3389/fimmu.2020.01677
Cyclic Peptide [R4W4] in Improving
the Ability of First-Line Antibiotics to
Inhibit Mycobacterium tuberculosis
Inside in vitro Human Granulomas
Joshua Hernandez 1,2, David Ashley 1,2, Ruoqiong Cao 3, Rachel Abrahem 1,2,
Timothy Nguyen 2, Kimberly To 1, Aram Yegiazaryan 1, Ajayi Akinwale David 4,
Rakesh Kumar Tiwari 4* and Vishwanath Venketaraman 1,2*
1Graduate College of Biomedical Sciences, Western University of Health Sciences, Pomona, CA, United States, 2College of
Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, United States, 3Department of
Basic Medical Sciences, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona,
CA, United States, 4Department of Biomedical and Pharmaceutical Sciences, Center for Targeted Drug Delivery, Chapman
University School of Pharmacy, Harry and Diane Rinker Health Science Campus, Irvine, CA, United States
Tuberculosis (TB) is currently one of the leading causes of global mortality. Medical
non-compliance due to the length of the treatment and antibiotic side effects has led
to the emergence of multidrug-resistant (MDR) strains of Mycobacterium tuberculosis
(M. tb) that are difficult to treat. A current therapeutic strategy attempting to circumvent
this issue aims to enhance drug delivery to reduce the duration of the antibiotic regimen
or dosage of first-line antibiotics. One such agent that may help is cyclic peptide [R4W4],
as it has been shown to have antibacterial properties (in combination with tetracycline)
against methicillin-resistant Staphylococcus aureus (MRSA) in the past. The objective of
this study is to test cyclic peptide [R4W4] both alone and in combination with current
first-line antibiotics (either isoniazid or pyrazinamide) to study the effects of inhibition of
M. tb inside in vitro human granulomas. Results from our studies indicate that [R4W4] is
efficacious in controlling M. tb infection in the granulomas and has enhanced inhibitory
effects in the presence of first-line antibiotics.
Keywords: cyclic peptide, tuberculosis, host–bacteria interaction, cytokine, antimicrobial peptides
INTRODUCTION
Mycobacterium tuberculosis (M. tb) is the etiological agent that is responsible for causing
tuberculosis (TB). According to theWorld Health Organization (WHO), it is estimated that around
9 million people are suffering from active TB disease with an approximate global mortality of 1.43
million people annually (1, 2). Furthermore, about a quarter of the world’s population is affected
with latent TB (1, 2).
Current treatment for drug-sensitive TB includes first-line antibiotics, which are administered
for approximately 6–9 months (3). Although treatment may be effective, problems with drug
toxicity can lead to severe side effects, interfering with patients’ compliance withmedical treatment.
Non-compliance to treatment often leads to the emergence of multidrug-resistant (MDR) strains
ofM. tb and the development of MDR-TB, which is difficult to treat, highlighting the need for new
therapeutic strategies.
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FIGURE 1 | Chemical structure of cyclic peptide [R4W4].
Novel therapeutic approaches that can achieve complete cure
along with reduced duration of treatment and dosage of first-
line anti-TB drugs are highly warranted. These strategies may
be crucial in alleviating drug side effects and in addressing
patient non-compliance.
Antimicrobial peptides (AMPs) are one such alternative
therapeutics against antibiotic-resistant pathogens since they
may act as effectors and regulators of the immune system as well
as inhibitors of bacterial cell growth (4). Additionally, there are
cell-penetrating peptides (CPPs) that share amphiphilicity and
cationic structural properties with antimicrobial peptides. Cell-
penetrating peptides are particularly interesting since they may
help deliver other drugs intracellularly due to their ability to
move across the eukaryotic cell membrane. In the grand scheme,
it is thought that the correlation between antimicrobial activity
and cell-penetrating property may be due to the interaction
between positively charged amphiphilic peptides and bacterial
membranes that have negatively charged components (4). One
such antimicrobial peptide is cyclic peptide [R4W4], which has a
cyclic structure consisting of four arginine and four tryptophan
residues (Figure 1), enabling it to interact with cell membranes
and deliver cargo. We, therefore, tested the effects of [R4W4]
both alone and in combination with the first-line antibiotics
in restricting the growth of M. tb inside the in vitro generated
human granulomas.
Our study findings indicate that [R4W4] causes a significant
decrease in the viability of M. tb and works effectively with first-
line antibiotics such as isoniazid (INH) and pyrazinamide (PZA)
by modulating the levels of cytokine release, oxidative stress,
and autophagy.
MATERIALS AND METHODS
Human Subjects and Whole Blood
Collection
In this study, we recruited eight healthy human subjects aged
between 18 and 65 years irrespective of other demographic
characteristics. Subjects were excluded if they self-reported ever
having a positive purified protein derivative (PPD) skin test, a
Bacille Calmette-Guerin (BCG) vaccination, a history of excessive
alcohol intake, and/or chronic Hepatitis B or C infection(s).
Informed consent was obtained from each subject prior to the
initiation of any research procedures. After obtaining written
informed consent, ∼35ml of whole blood was obtained from
each subject using Acid Citrate Dextrose tubes by research
nursing staff at the WesternU Health Patient Care Center. All
studies were approved by the Institutional Review Board (IRB)
and the Institutional Biosafety Committee (IBC) of the Western
University of Health Sciences. All study participants were above
the legal age of consent at the time of participation, and written
informed consent was obtained from all volunteers prior to
participation in the study.
Isolation of Peripheral Blood Mononuclear
Cells
Whole blood samples were distributed between two 50-ml
conical tubes containing Ficoll-Histopaque (Sigma, St. Louis,
MO, USA) at a 1:1 ratio. Following centrifugation (1,800
rpm for 30min), peripheral blood mononuclear cells (PBMCs)
were collected and washed twice with sterilized 1× phosphate
buffer saline (PBS) (Sigma, St. Louis, MO, USA). PBMCs were
suspended in RPMI with 5% human AB serum (Sigma, St.
Louis, MO, USA). Cell counts were achieved using Trypan Blue
exclusion staining and a hemocytometer.
Infection, Treatment, and Termination of
PBMC-Derived Granulomas
PBMCs (6 × 105) with verified counts were infected with M.
tb (Erdman strain) using a multiplicity of infection ratio of
1:10 (M. tb: PBMCs) and distributed into sterile cell culture
24-well plates (Corning, Corning, NY, USA). Two wells per
category contained cover glasses that were used to collect
in vitro granulomas for staining procedures. Treatments were
applied one time in quadruplicate using the following categories:
Control (sham treatment), INH, PZA, [R4W4] (4µg/ml), [R4W4]
(8µg/ml), INH and [R4W4] (4µg/ml), INH and [R4W4]
(8µg/ml), PZA and [R4W4] (4µg/ml), and PZA and [R4W4]
(8µg/ml). All treatments that included INH and PZA used
minimum inhibitory concentrations (0.125µg/ml and 50µg/ml,
respectively). Treated infected PBMCs were cultured for 8 days
at 37◦C in the presence of 5% CO2 for granuloma formation. At
the conclusion of the 8-day incubation, each well was terminated.
Supernatants of each well were collected and aliquoted into sterile
Eppendorf tubes by treatment categories. Sterile cold 1 × PBS
was added into each experimental well without cover glasses to
lyse the in vitro granulomas. To further dislodge the in vitro
granulomas, each well was scraped using a sterile micropipette.
Lysates from each category were then collected and aliquoted into
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sterile Eppendorf tubes by treatment category. Wells with cover
glasses were treated with 4% paraformaldehyde (PFA) for 1 h at
room temperature to affix in vitro granulomas to their respective
cover glasses for imaging analyses. PFA-treated wells were also
washed three times with PBS to remove any cellular debris that
could impede imaging analyses.
Quantification of IntracellularM. tb Survival
In order to quantify the intracellular survival of M. tb in these
treated in vitro granulomas, plates containingMiddlebrook 7H11
agar media (Hi Media, Santa Maria, CA, USA) supplemented
with albumin-dextrose-catalase (ADC) (GEMINI, Calabasas,
CA) were inoculated with previously collected supernatants and
lysates. Plates were then incubated at 37◦C for a minimum of 4
weeks. Plates were then read, and colony-forming units (CFUs)
were counted.
Cytokine Measurements
Cytokine analyses were conducted to quantify the produced
levels of TNF-α, IFN-γ, and IL-10 in collected supernatant
samples. The sandwich enzyme-linked immunosorbent assay
(ELISA) was used. Assays and analyses were conducted per the
assay manufacturer’s protocol (Invitrogen, Carlsbad, CA, USA).
Imaging of in vitro Granulomas
Cover glasses with fixed in vitro granulomas were permeabilized
with Triton-X for 2min and stained overnight with FITC-
conjugated CellROX and with antibodies against LC3B
conjugated with PE. Cover glasses were washed with PBS and
mounted on clean glass slides with mounting media containing
4
′
,6-diamidino-2-phenylindole (DAPI). Slides were observed
under the fluorescent microscope. Fluorescent images were
captured, and the fluorescent intensity was quantified using the
ImageJ software.
Statistical Analysis
All data analyses for this study were conducted using GraphPad
Prism 8.0. (version 8, GraphPad, San Diego, CA, USA). A one-
way ANOVA (analysis of variance) with Tukey corrections was
performed for datasets greater than two groups. Reported values
are in means with each respective category. Data represent
±SE from experiments performed in eight different individuals.
Analyses with a p < 0.05 was considered statistically significant.
RESULTS AND DISCUSSION
Antimicrobial peptides are promising candidates that can be
used as adjunctive therapy for TB. The structural and functional
qualities of the synthetic AMP, [R4W4], led us to test its
efficacy against M. tb., which has a thick peptidoglycan layer
along with other lipid layers on the cell wall. [R4W4] has
already been shown to have potent antibacterial activity against
pathogenic gram-positive bacteria such as methicillin-resistant
Staphylococcus aureus (MRSA) with an inhibitory concentration
(MIC) of 2.67µg/ml (1.95µM). In addition, a follow-up 24-
h study showed bactericidal activity against MRSA with the
combination of two times the MIC of [R4W4] and four times
the MIC of tetracycline (0.5µg/ml) (4). Cytotoxicity studies
of [R4W4] have been reported using MTS proliferation assay
against two cancer cell lines (human ovarian adenocarcinoma
SK-OV-3 and human leukemia CCRF-CEM) and one normal
human embryonic kidney HEK 293T cell line at 24-h incubation.
The cyclic peptide [R4W4] demonstrated more than 84% cell
viability at a concentration of 20.5µg/ml in both cancer and
normal cell lines (4). Furthermore, [R4W4] showed minimal
hemolytic activity by showing <10% hemolysis of normal red
blood cells at the concentration of 128µg/ml. Therefore, these
studies demonstrate negligible or minimum cytotoxicity of
[R4W4] up to 20.5µg/ml to the normal and cancerous cell
lines. A fluorescent-labeled [R4W4] peptide was synthesized
and reported to disperse into the nucleus and cytoplasm. This
demonstrated the transporter property of the [R4W4] peptide.
Furthermore, it has been reported that cyclic peptides have
higher stability against proteases and found resistant toward
proteolytic degradation as compared to linear peptides (5). Cyclic
peptides have demonstrated stability under disease condition,
and some of them are successfully used as drugs, including
vancomycin, daptomycin, polymyxin B, colistin, caspofungin,
and cyclosporine (6–8). A series of cyclic WR peptides has been
reported to be stable against serum and found to have molecular
transporter properties (9, 10). Therefore, [R4W4] will be stable
against proteases due to very similar amino acid composition
and cyclic nature. As [R4W4] has shown bactericidal activity
(alongside tetracycline) against MRSA (4), it is an attractive
candidate that can be tested along with first-line anti-TB drugs
againstM. tb.
Two of the first-line antibiotics used to treat active TB
are INH and PZA, both of which have MICs of 0.125 and
50µg/ml, respectively, against M. tb. In our past studies, one-
time treatment of in vitro M tb-infected granulomas (or immune
cell clusters) with lone INH and PZA at MIC did not result in
complete clearance ofM. tb. (11). We, therefore, tested the effects
of [R4W4] both alone and in combination with either INH or
PZA against M. tb in the in vitro granulomas generated from
PBMCs isolated from healthy subjects.
We first tested the direct antimycobacterial effects of [R4W4]
added at 4 and 8µg/ml concentrations to static cultures of
Erdman strain ofM. tb. Static cultures ofM. tbwere grown in 7H9
media in the presence and absence of [R4W4] (added at 4µg/ml
and 8µg/ml) and the growth of M. tb was monitored for 8 days
(Figure 2A). The selection of the two concentrations (4µg/ml
and 8µg/ml) of [R4W4] was based on the rationale of reported
MIC values of peptide [R4W4] against MRSA (4, 12, 13). The
bacterial suspension was plated on 7H11 media and incubated
for 4 weeks for colony formation. Compared to the untreated
control group, M. tb survival (demonstrated by CFU counts) in
7H9 was significantly reduced by 2.2-fold in the group treated
with [R4W4] at 4µg/ml concentration (p= 0.0223) (Figure 2A).
There was also reduced M. tb survival in the group treated with
[R4W4] at 8µg/ml, but this was not a statistically significant
finding (p= 0.1709) (Figure 2A).
We then determined the viability of M. tb inside the in
vitro granulomas treated with [R4W4] at 4 and 8µg/ml. The
sham control group of human M. tb-infected granulomas was
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FIGURE 2 | Efficacy of [R4W4] against M. tb. Sensitivity Erdmann strain of M. tb to the cyclic peptide [R4W4] added at 4 and 8µg/ml concentrations. *P < 0.05 when
comparing CFUs at the 8-day time point of 4µg/ml [R4W4]-treated Erdman strain to untreated control category (A). Effects of [R4W4] in altering the viability in M. tb in
the in-vitro granulomas (B). Effects of [R4W4] in altering the production of TNF-α (C). Effects of [R4W4] in altering the levels of IFN-γ (D). Effects of [R4W4] in altering
the production of IL-10 (E). Effects of [R4W4] on reactive oxygen species production (F). Mean fluorescent intensity of CellROX-stained (green fluorescent) control
granulomas (G), [R4W4] (4µg/ml)-treated (H), and [R4W4] (8µg/ml)-treated granulomas (I). Effects of [R4W4] on LC3B expression (J). Mean fluorescent intensities of
LC3B-stained (PEt)control granulomas (K), [R4W4] (4µg/ml)-treated (L), and [R4W4] (8µg/ml)-treated granulomas (M). Anti-LC3B conjugated with PE and CellROX
conjugated with FITC were applied on the same specimen. Fluorescent images were captured for each marker either from the same field or from a different
representative field. Reported values are in means with each respective category. Data represent ± SE from experiments performed from eight different individuals.
Analysis of figures utilized a one-way ANOVA with Tukey test. The p value above 0.05 is not considered significant, one symbol (* or #) denotes significant difference
below 0.05, two symbols (** or ##) denote significant difference below 0.005, three symbols (*** or ###) denote significant difference below 0.0005, and four symbols
(**** or ####) denote significant difference below 0.0001. An asterisk (*) indicates comparison to the direct previous category. A hash mark (#) indicates comparison
between one category and a previous category that is one column before it. A dollar sign ($) indicates comparison between one category and a previous category that
is two columns before it.
compared against in vitro granulomas treated with [R4W4] at
4 and 8µg/ml, respectively. Compared to the control group,
intracellular M. tb survival was significantly reduced in both
groups treated with [R4W4] at 4µg/ml (p= 0.0348) and 8µg/ml
concentrations (p = 0.0423) (Figure 2B). In comparison to the
untreated granulomas, the fold reduction in the CFUs was 10.86
and 5.95 for granulomas treated with [R4W4] at 4 and 8µg/ml,
respectively. However, there was no significant difference in the
intracellular M. tb survival between the groups treated with 4
and 8µg/ml (p = 0.2719) (Figure 2B). These findings indicate
that the treatment of in vitro granulomas with R4W4 caused a
reduction in theM. tb burden (Figure 2B).
To understand the effects of [R4W4] in altering the underlying
immune effector mechanisms against M. tb infection, we
first measured the levels of several related cytokines that
cause the activation (TNF-α and IFN-γ) and inhibition (IL-
10) of immune effector mechanisms. TNF-α expression was
significantly downregulated by [R4W4] at both 4µg/ml (p =
0.036) and 8µg/ml concentrations (p = 0.0003) compared to
sham-treated control categories (Figure 2C). In comparison to
the untreated granulomas, the fold reduction in the levels of
TNF-α was 2 and 3.3 for granulomas treated with [R4W4] at 4
and 8µg/ml, respectively. TNF-α, a pro-inflammatory cytokine,
activates the effector immune functions and causes recruitment
of immune cells to form a solid and stable granuloma to contain
M. tb infection (14–18). Excess TNF-α can cause cell death by
necrosis, leading to inflammation (19, 20). Our findings indicate
a positive correlation between diminished numbers of M. tb in
[R4W4]-treated granulomas with a corresponding decrease in
the levels of TNF-α explaining the immunomodulatory effects
of [R4W4].
IFN-γ is crucial in both innate and adaptive immunity,
acting as a macrophage activation factor and mediating MHC
molecule expression (21). There was a 2.5-fold increase in IFN-γ
production in the supernatants from in vitro granulomas treated
with 4µg/ml concentration of [R4W4] (p = 0.0161) compared
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to sham control (Figure 2D). In our previously published study
(18), we demonstrated that IFN-γ increase was associated with
enhanced phagosome acidification and improved killing ofM. tb
in the in vitro granulomas. Therefore, higher amounts of the IFN-
γ release may therefore serve as an additional effector mechanism
by which in vitro granulomas treated with 4µg/ml of [R4W4]
controlM. tb infection.
IL-10 is an immune-suppressive cytokine that can inhibit
phagosome–lysosome fusion and dampen other effector
responses against M. tb infection (11, 22–24). We observed
a notable decrease in the levels of IL-10 in [R4W4]-treated
granulomas at both concentrations (4 and 8µg/ml). These
findings indicate that [R4W4] supplementation augments
immune responses againstM. tb infection by downregulating the
levels of IL-10 (Figure 2E) and by increasing the levels of IFN-γ
(Figure 2D).
It is well-known that oxidative stress generated during M.
tb infection can contribute to both protection and pathogenesis
(25). M. tb infection triggers the release of pro-inflammatory
cytokines and reactive oxygen species (ROS) leading to oxidative
stress. It is important to point out that the survival of M.
tb is dependent on the extent of ROS produced by the host
immune cells. Exacerbation in the levels of ROS can damage
the immune cells causing diminishment in the effector responses
againstM. tb infection (25, 26). CellROX staining was performed
to determine the extent of oxidative stress in sham control
and [R4W4]-treated granulomas (Figure 2F). In comparison
to the control group, there was a significant decrease in the
intensity of CellROX staining in the [R4W4]-treated granulomas
(Figures 2F–I). In comparison to the untreated granulomas, the
fold reduction in the intensity of CellROX staining was 1.3
and 2.1 for granulomas treated with [R4W4] at 4 and 8µg/ml,
respectively. This significant reduction in the mean fluorescence
intensity implies attenuation of oxidative stress levels. These
data further illustrate that reducing the oxidative stress restores
favorable immune responses against M. tb infection. TNF-α
plays a central role in triggering the inflammatory response
via ROS production (18, 27, 28). Additionally, ROS can induce
TNF-α production (18, 27). Our study findings therefore
confirm this direct link between TNF-α levels and oxidative
stress and the effects of [R4W4] in downregulating the levels
of both.
Autophagy is a self-degradative process, which plays a critical
role in promoting cellular senescence, antigen presentation on
the cell surface, and eliminating intracellular waste aggregates
and damaged organelles, thereby preventing necrosis (29–31).
It has been reported that autophagy functionally benefits some
diseases such as cancer, cardiomyopathy, diabetes, liver disease,
and infections (29–31). LC3B is a mammalian homolog of the
yeast ATG8 protein, which is a ubiquitin-like protein related
to autophagosomal membranes (32, 33). Therefore, LC3B is an
important and direct marker used for detecting autophagy levels
(32, 33). The LC3B protein in the granulomas were stained by
an anti-LC3B antibody tagged with PE, a red fluorescent dye.
Increased LC3B expression is indicative of increased autophagy.
We observed that the mean fluorescence intensity of LC3B
was significantly elevated in the [R4W4]-treated granulomas
at both concentrations compared to the untreated granulomas
(Figures 2J–M). In comparison to the untreated granulomas,
the fold increase in the expression levels of LC3B was 2.4 and
2.6 for granulomas treated with [R4W4] at 4 and 8µg/ml,
respectively. Our results specify that autophagy may be one of the
immune effector mechanisms by which [R4W4]-treated in vitro
granulomas controlM. tb infection.
We also tested the effects of [R4W4] and first-line antibiotics
(INH or PZA) in reducing the burden of M. tb in the in vitro
granulomas. Infected PBMCs were treated with [R4W4] at 4
and 8µg/ml concentrations and cultured in the presence and
absence of INH or PZA at their respective MIC. Consistent with
our previous observations, there was a significant and 18-fold
reduction in viability of M. tb in INH-treated granulomas (p
= 0.0314). Treatment with INH in conjunction with [R4W4]
at either 4µg/ml (p = 0.0287) or 8µg/ml (p = 0.0292)
concentration resulted in a further reduction in the viability of
M. tb when compared with the control category (Figure 3A).
In comparison to the untreated granulomas, the fold reduction
in the viability of M. tb was 104 and 57 in granulomas treated
with INH + [R4W4] at 4µg/ml and INH + [R4W4] 8µg/ml,
respectively. Although these findings were statistically significant,
there were no significant statistical findings when comparing the
INH category with INH treatment in conjunction with [R4W4]
at 4µg/ml (p= 0.2787) and 8µg/ml (p= 0.3803) concentrations
(Figure 3A).
The reduction in the viability of M. tb in INH + [R4W4]-
treated granulomas was accompanied by a significant
diminishment in the levels of TNF-α (p = 0.0113) along
with a notable decrease in the levels of IL-10 (p = 0.1336) in
the granuloma supernatants from INH + [R4W4] treatment
categories when compared to untreated and INH-alone
treated groups (Figures 3B,D). INH + [R4W4] treatment
did not result in any significant changes in the production
of IFN-γ (Figure 3C). Furthermore, treatment with INH +
[R4W4] resulted in a significant decrease in the intensity
of CellROX when compared to INH alone and control
categories (Figures 3E–I). INH + [R4W4] treatment also
resulted in a significant decrease in the intensity of LC3B
staining when compared to the INH-alone treatment group.
However, when compared to the control category, INH +
[R4W4] treatment resulted in a statistically significant 2-fold
increase in the intensity of LC3B staining (Figures 3J–N).
Our results demonstrate that INH, when given in conjunction
with [R4W4], decreases M. tb burden and downregulates
oxidative stress and production of TNF-α and IL-10, when
compared to lone INH treatment and control. Although the
combination of INH + [R4W4] did not increase the expression
of LC3B when compared to treatment with INH alone, INH
+ [R4W4] treatment downregulated the intensity of CellROX
staining and diminished the production of TNF-α and IL-10.
Although TNF-α plays a central role in the formation and
maintenance of granulomas, overexpression of TNF-α has
also been linked to many inflammatory and autoimmune
diseases (14–20). IL-10, an immunosuppressive cytokine, can
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FIGURE 3 | Efficacy of INH and INH + [R4W4] against M. tb. Effects of INH and INH + [R4W4] (added at 4 and 8µg/ml concentrations) in altering the viability in M. tb
in the in vitro granulomas (A). Effects of INH and INH + [R4W4] (added at 4 and 8µg/ml concentrations) in interfering with the production of TNF-α (B). Effects of INH
and INH + [R4W4] (added at 4 and 8µg/ml concentrations) in interfering with the production of IFN-γ (C). Effects of INH and INH + [R4W4] (added at 4 and 8µg/ml
concentrations) in interfering with the production of IL-10 (D). Effects of INH and INH + [R4W4] (added at 4 and 8µg/ml concentrations) on reactive oxygen species
production (E). Mean fluorescent intensity of CellROX-stained (green fluorescent) control granulomas (F), INH-treated (G), INH + [R4W4] (4µg/ml)-treated (H), and
INH + [R4W4] (8µg/ml)-treated granulomas (I). Effects of INH and INH+ [R4W4] (added at 4 and 8µg/ml concentrations) on LC3B expression (J). Mean fluorescent
intensities of LC3B-stained (red fluorescent) control granulomas (K), INH-treated (L), INH + [R4W4] (4µg/ml)-treated (M), and INH + [R4W4] (8µg/ml)-treated
granulomas (N). Anti-LC3B conjugated with PE (red) and CellROX conjugated with FITC (green) were applied on the same specimen. Fluorescent images were
captured for each marker either from the same field or from a different representative field. Reported values are in means with each respective category. Data
represents ± SE from experiments performed from 8 different individuals. Analysis of figures utilized a one-way ANOVA with Tukey test. The p value above 0.05 is not
considered significant, one symbol (*, #, or $) denotes significant difference below 0.05, two symbols (**, ##, or $$) denote significant difference below 0.005, three
symbols (***, ###, or $$$) denote significant difference below 0.0005, and four symbols (****, ####, or $$$$) denote significant difference below 0.0001. An asterisk (*)
indicates comparison to the direct previous category. A hash mark (#) indicates comparison between one category and a previous category that is one column before
it. A dollar sign ($) indicates comparison between one category and a previous category that is two columns before it.
downregulate the effector functions of macrophage against M.
tb infection (11, 22–24, 34). Therefore, combination of [R4W4]
with INH can downregulate oxidative stress and production
of TNF-α and IL-10, which in turn can favor improved
control of M. tb infection when compared to treatment with
INH alone.
When compared to the untreated control category, PZA
treatment also resulted in a statistically significant and 30-fold
reduction in the viability ofM. tb in the granulomas (Figure 4A)
(p = 0.0302). A further decrease in the viability of M. tb was
observed with PZA + [R4W4] treatments. The fold reduction
in the viability of M. tb was 511 and 136 in granulomas
treated with PZA + [R4W4] at 4µg/ml and PZA + [R4W4]
8µg/ml, respectively, when compared to untreated granuloma.
The levels of TNF-α, IL-10, and IFN-γ were measured in the
granuloma supernatants from control, PZA-treated, and PZA +
[R4W4]-treated groups (Figures 4B–D). There was a statistically
significant and 3.3-fold reduction in the levels of TNF-α in the
PZA-treated group when compared to the control (Figure 4B).
PZA + [R4W4] treatment resulted in a further significant
decrease in the production of TNF-αwhen compared to the PZA-
alone category and control groups. PZA + [R4W4] treatment
also resulted in a significant decrease in the production of IL-10
(Figure 4D).
Although not significant, PZA+ [R4W4] (4µg/ml) treatment
resulted in an increase in the levels of IFN-γ (Figure 4C). PZA
treatment resulted in attenuation in the fluorescence intensity of
CellROX. However, the granulomas treated with PZA + [R4W4]
showed a significant increase in the intensity of CellROX staining
compared to the PZA-alone group (Figures 4E–I). There was
increased intensity of LC3B staining in PZA-treated granulomas
compared to the untreated control group. PZA + [R4W4]
treatment caused a significant increase in the intensity of LC3B
staining compared to the control and PZA-alone group. In
comparison to the untreated granulomas, the fold increase in
the intensity of LC3B staining was 2 and 2.4 in granulomas
Frontiers in Immunology | www.frontiersin.org 6 August 2020 | Volume 11 | Article 1677
Hernandez et al. Cyclic Peptide and Mycobacterium tuberculosis
FIGURE 4 | Efficacy of PZA and PZA + [R4W4] against M. tb. Effects of PZA and PZA + [R4W4] (added at 4 and 8µg/ml concentrations) in altering the viability in M.
tb in the in vitro granulomas (A). Effects of PZA and PZA + [R4W4] (added at 4 and 8µg/ml concentrations) in interfering with the production of TNF-α (B). Effects of
PZA and PZA + [R4W4] (added at 4 and 8µg/ml concentrations) in interfering with the production of IFN-γ (C). Effects of PZA and PZA + [R4W4] (added at 4 and
8µg/ml concentrations) in interfering with the production of IL-10 (D). Effects of PZA and PZA + [R4W4] (added at 4 and 8µg/ml concentrations) on reactive oxygen
species production (E). Mean fluorescent intensity of CellROX-stained (green fluorescent) control granulomas (F), PZA-treated (G), PZA + [R4W4] (4µg/ml)-treated
(H), and PZA + [R4W4] (8µg/ml)-treated granulomas (I). Effects of PZA and PZA+ [R4W4] (added at 4 and 8µg/ml concentrations) on LC3B expression (J). Mean
fluorescent intensities of LC3B-stained (red fluorescent) control granulomas (K), PZA-treated (L), PZA + [R4W4] (4µg/ml)-treated (M), and PZA + [R4W4] (8µg/ml)-
treated granulomas (N). Anti-LC3B conjugated with PE (red) and CellROX conjugated with FITC (green) were applied on the same specimen. Fluorescent images were
captured for each marker either from the same field or from a different representative field. Reported values are in means with each respective category. Data
represents ± SE from experiments performed from 8 different individuals. Analysis of figures utilized a one-way ANOVA with Tukey test. The p value above 0.05 is not
considered significant, one symbol (*, #, or $) denotes significant difference below 0.05, two symbols (**, ##, or $$) denote significant difference below 0.005, three
symbols (***, ###, or $$$) denote significant difference below 0.0005, and four symbols (****, ####, or $$$$) denote significant difference below 0.0001. An asterisk (*)
indicates comparison to the direct previous category. A hash mark (#) indicates comparison between one category and a previous category that is one column before
it. A dollar sign ($) indicates comparison between one category and a previous category that is two columns before it.
treated with PZA + [R4W4] at 4µg/ml and PZA + [R4W4] at
8µg/ml, respectively (Figures 4J–N). Our results indicate that
when compared to the PZA-alone category, treatment with PZA
+ [R4W4] caused increased production of IFN-γ, decreased
levels of IL-10, increased autophagy, and improved control of
M. tb infection. These findings further support the previous
findings that decreased IL-10 along with increased IFN-γ will
favor effective control ofM. tb infection (21).
Our study findings demonstrate that [R4W4] elicits direct
antimycobacterial ability against virulent Erdman strain of M.
tb at 4µg/ml. Treatment of in vitro granulomas with [R4W4]
both alone and in combination with first-line antibiotics such
as INH and PZA at MIC concentration resulted in a further
decrease in the viability of M. tb. The addition of [R4W4] to
granulomas both in the presence and absence of PZA led to a
reduction in the levels of TNF-α and IL-10, and elevation in the
levels of autophagy. Our study findings, therefore, indicate that
[R4W4] causes a significant decrease in the viability ofM. tb and
works in conjunction with first-line antibiotics by modulating
the levels of cytokine release and autophagy. In conclusion,
we believe that [R4W4], along with anti-TB treatment, would
not only attenuate the side effects of antibiotics but can also
enhance the immune responses to eliminate the active M.
tb infection.
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